Human hair

Hair Colour Chart Experts Guangzhou Boyan Meet Announces Ground-Breaking Fiber, and New Beauty range of Hair Care Hair Styling at Cosmoprof Asia Digital Week

Retrieved on: 
Thursday, November 5, 2020

With the launch of their new hair colour chart fiber, they are a big and exciting step closer.

Key Points: 
  • With the launch of their new hair colour chart fiber, they are a big and exciting step closer.
  • As a result the company will be launching a pioneering new hair colour chart fiber and a new brand of products for hair dye, care and styling, Gouallty, at Cosmoprof Asia Digital Week.
  • And, considering their expertise in hair, who else will be better than Boyan to create a brand of hair care, hair dying and hair styling products together?
  • Guangzhou Boyan Meet was founded in 2005 in Guangzhou, China, and since then has become one of the top hair colour chart manufacturers in Asia.

Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Retrieved on: 
Tuesday, November 3, 2020

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA1, the first Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA1, the first Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata.
  • Based on the results from our Phase 2 program, we believe CTP-543 has the potential to offer patients a best-in-class treatment for moderate to severe alopecia areata, said James V. Cassella, Ph.D., Chief Development Officer, Concert Pharmaceuticals.
  • The end-of-phase 2 meeting with the FDA was held following positive results from a dose-ranging Phase 2 trial of CTP-543 in patients with moderate to severe alopecia areata.
  • There are millions of people around the world affected by and living with alopecia areata, said Andy Bryant, Acting Chief Executive Officer of the National Alopecia Areata Foundation.

Concert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study in Alopecia Areata During Late-Breaking Session at EADV Congress

Retrieved on: 
Thursday, October 29, 2020

These data were presented during the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress.

Key Points: 
  • These data were presented during the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress.
  • More than 90% of eligible patients have enrolled in the CTP-543 long-term extension study.
  • Treatment with CTP-543 shows continued maintenance of hair regrowth across the long-term extension study.
  • The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017.

InventHelp Inventor Develops Improved Pre-Surgical Shave Accessory for Hospitals (RVS-126)

Retrieved on: 
Thursday, October 29, 2020

This patent pending invention provides a more advanced & effective way to shave a patient prior to surgery.

Key Points: 
  • This patent pending invention provides a more advanced & effective way to shave a patient prior to surgery.
  • In doing so, it offers an improved alternative to traditional razors versus surgical clippers with the multi-usage of tape roll application during surgical preparation.
  • This device also features a self-lubricating shaving blade with a combination of an antiseptic sterile gel solution enclosed inside a prefilled cartridge insert.
  • The invention features a compact design that is convenient and easy to use so it is ideal for hospitals, surgical medical facilities and ambulatory surgical centers.

Concert Pharmaceuticals Announces Publication on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology

Retrieved on: 
Thursday, October 22, 2020

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Journal of Investigative Dermatology published results from a survey designed to understand the burden and everyday experience for patients living with moderate-to-severe alopecia areata.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Journal of Investigative Dermatology published results from a survey designed to understand the burden and everyday experience for patients living with moderate-to-severe alopecia areata.
  • The survey was conducted by the National Alopecia Areata Foundation (NAAF) and the published results were authored by four leading medical experts in dermatology, with funding for the study provided by Concert Pharmaceuticals.
  • We are hopeful that we can move away from complacency about alopecia areata and enter an era of more effective treatment.
  • Key findings of the survey show that patients with alopecia areata suffer significantly increased burden of illness including:
    Alopecia areata has a negative impact on many aspects of daily life, extending far beyond cosmetic concerns.

Alopecia Market Size Worth USD 5,250.8 Million by 2027 | CAGR of 8.9%: Emergen Research

Retrieved on: 
Tuesday, October 13, 2020

VANCOUVER, BC, Oct. 13, 2020 /PRNewswire/ -- The Global Alopecia Market is projected to be worth USD 5,250.8 Million by 2027, according to a current analysis by Emergen Research.

Key Points: 
  • VANCOUVER, BC, Oct. 13, 2020 /PRNewswire/ -- The Global Alopecia Market is projected to be worth USD 5,250.8 Million by 2027, according to a current analysis by Emergen Research.
  • The alopecia market is projected to experience rapid growth by the year 2027.
  • For instance, alopecia areata, a chronic, autoimmune disorder that affects growing hair follicles resulting in nonscarring focal hair loss, has global prevalence.
  • To get leading market solutions, visit the link below:
    Emergen Research has segmented the global alopecia market on the basis of type, application, end-users, distribution channel, and region:

Alopecia Market Size Worth USD 5,250.8 Million by 2027 | CAGR of 8.9%: Emergen Research

Retrieved on: 
Tuesday, October 13, 2020

- Market Size USD 2,650.8 Million in 2019, Market Growth - CAGR of 8.9%, Market Trends Growing awareness about the disease in developed nations

Key Points: 
  • - Market Size USD 2,650.8 Million in 2019, Market Growth - CAGR of 8.9%, Market Trends Growing awareness about the disease in developed nations
    VANCOUVER, BC, Oct. 13, 2020 /PRNewswire/ -- The Global Alopecia Market is projected to be worth USD 5,250.8 Million by 2027, according to a current analysis by Emergen Research.
  • The alopecia market is projected to experience rapid growth by the year 2027.
  • For instance, alopecia areata, a chronic, autoimmune disorder that affects growing hair follicles resulting in nonscarring focal hair loss, has global prevalence.
  • To get leading market solutions, visit the link below:
    Emergen Research has segmented the global alopecia market on the basis of type, application, end-users, distribution channel, and region:

Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress

Retrieved on: 
Tuesday, October 13, 2020

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker oral presentation at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker oral presentation at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress.
  • The oral presentation will highlight new data from an ongoing open label extension study evaluating long-term safety and treatment effects of CTP-543 in patients with moderate to severe alopecia areata.
  • The details of the presentation are as follows:
    Title: Initial Results from a Long-Term, Open-Label Extension Study with CTP-543, an Oral Janus Kinase Inhibitor, in Patients with Moderate to Severe Alopecia Areata
    Location: EADV Virtual Meeting.
  • Registration is required to participate: https://eadvvirtualcongress.org/registration/
    CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2.

Histogen Announces Completion of Final Dosing Timepoint Milestone in its 1b/2a Trial for Androgenic Alopecia in Men

Retrieved on: 
Monday, October 5, 2020

We believe HST-001 has the potential to stimulate new long-lasting hair growth in contrast to the two FDA approved therapies that focus on reducing hair loss.

Key Points: 
  • We believe HST-001 has the potential to stimulate new long-lasting hair growth in contrast to the two FDA approved therapies that focus on reducing hair loss.
  • This blinded, randomized, placebo controlled, single site study has enrolled 36 subjects with male pattern hair loss using a 2:1 randomization of HST-001 to placebo.
  • HST-001, or Hair Stimulating Complex (HSC), is intended to be a physician-administered therapeutic for hair loss.
  • HSC is anticipated to be a relatively safe, minimally invasive treatment that promotes new hair growth where existing treatments only reduce hair loss.

Johnny Slicks #SHAVETOBER Campaign For St. Jude Children's Hospital

Retrieved on: 
Saturday, October 3, 2020

Johnny Slicks shave soap is especially great for frequent shavers, because you can keep your skin baby-bottom smooth, avoiding the razor burn and discomfort caused by lower-quality shave creams.

Key Points: 
  • Johnny Slicks shave soap is especially great for frequent shavers, because you can keep your skin baby-bottom smooth, avoiding the razor burn and discomfort caused by lower-quality shave creams.
  • Starting November 1st, 10% of all profits from each of our beard products, the Beard Oil and Beard Wash, will go toward our Johnny Slicks #NOSHAVENOVEMBER campaign for St. Jude Children's Hospital.
  • Johnny Slicks was formed when Marine John Raushi realized that the ingredients in the hair products he was modeling were causing his hair to thin prematurely.
  • We landed on St. Jude Children's Hospital, as it exists to support the health and well-being of children with cancer and their families."